CB Solutions, LLC.

Belkins
CB Solutions is an environmental and energy services provider, and a company that is dedicated to the renewal of the environment, through the exceptional achievement of innovative products created over many years of research and development. The combined experience of our staffs, of over 60 years of product development and environmental consulting, has allowed us to offer products which are second to none in a very competitive market. It is that competitive market, and ever-increasing regulations, that has given us the drive to achieve the exceptional.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

news image

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

news image

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

news image

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More

INDUSTRIAL IMPACT

AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

Amyris, Inc. | January 25, 2022

news image

Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer...

Read More
news image

MEDICAL

ENTOPSIS EXPLORING STRATEGIC ALTERNATIVES FOR ITS OPSISDX™ PLATFORM

Berkery, Noyes & Co. | October 08, 2021

Entopsis, Inc., the developer of an unbiased approach to diagnostics using bio-molecular signatures with a focus on oncology, announced that it has engaged Berkery Noyes & Co. as its financial advisor to assist the company in pursuing strategic alternatives for their OpsisDxTM platform. OpsisDxTM is a urine-based technology platform that shifts the focus away from conventional RNA and DNA approaches, offering a highly sensitive and specific diagnostic test for the detection of...

Read More
news image

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More
news image

GENAPSYS RAISES $75M TO BRING ITS TABLETOP DNA SEQUENCER TO ASIA AMID CORONAVIRUS OUTBREAK

FierceBiotech | February 06, 2020

Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. The company’s high-throughput sequencer—which sits on a tabletop and weighs less than 10 pounds—is being launched in South Korea, Singapore, Japan and China as part of more than 25 recently inked distribution deals....

Read More
news image

INDUSTRIAL IMPACT

AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

Amyris, Inc. | January 25, 2022

Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer...

Read More